Growth stocks have the potential to generate significant returns, because they frequently represent companies in emerging industries or with innovative products and services.
That said, not every growth stock can grow its revenue and earnings at a substantial rate over time. However, investors often have high hopes for clinical-stage biotech companies focused on finding a cure for life-threatening diseases. Biomea Fusion (BMEA), an emerging biotech player, is one of those companies we'll look at today.
